Table 5. Mcm5 signal test sensitivity in cancer patients categorized by PSA level, clinical stage and Gleason score.

	Pre-massage						Post-massage					Highest Mcm5 signal
	n	Mcm5, median (IQR)	Sensitivity % (CI)	P (n)*	P (t)†	n	Mcm5, median (IQR)	Sensitivity % (CI)	P (n)	P (t)	n	Mcm5, median (IQR)	Sensitivity % (CI)	P (n)	P (t)
PSA, ng ml–1
<5	25	2180 (<1800 to 4190)	56 (34–76)	—	—	20	3170 (1874 to 5587)	75 (51–91)	—	—	26	3170 (2152 to 5887)	81 (61–93)	—	—
5–15	26	2365 (<1800 to 3947)	62 (41–80)	0.77	0.21	23	3870 (2280 to 5160)	83 (61–95)	0.65	0.96	29	3870 (2250 to 5240)	79 (60–92)	0.95	0.80
>15	29	3440 (<1800 to 5075)	72 (53–87)	0.24	—	16	3290 (1914 to5037)	75 (48–93)	1.00	—	30	4065 (2450 to 5337)	83 (65–94)	0.88	—
Clinical stage
T1	23	2460 (<1800 to 5000)	61 (39–80)	—	—	18	4485 (3210 to 7797)	94 (73–100)	—	—	24	4505 (3007 to 6900)	92 (73–99)	—	—
T2	30	2210 (<1800 to 3140)	60 (41–77)	0.98	0.70	28	2625 (<1800 to 4240)	68 (48–84)	0.08	0.06	33	2680 (2045 to 4445)	79 (61–91)	0.33	0.05
T3/4	21	3470 (<1800 to 5290)	67 (43–85)	0.75	—	9	2560 (<1800 to 4300)	67 (30–93)	0.22	-	22	3500 (<1800 to 5330)	68 (45–86)	0.10	—
Gleason score
⩽6	32	2310 (<1800 to 3420)	62 (44–79)	—	—	24	3800 (2887 to5707)	87 (68–97)	—	—	32	3545 (2715 to 5707)	91 (75–98)	—	—
7	22	2125 (<1800 to 3580)	55 (32–76)	0.58	0.77	19	3660 (<1800 to 5160)	74 (49–91)	0.37	0.05	26	3375 (<1800 to 4830)	69 (48–86)	0.10	0.12
8–10	19	3530 (<1800 to 5660)	68 (43–87)	0.70	—	12	2340 (<1800 to 3212)	58 (28–85)	0.13	—	20	3255 (1942 to 5552)	75 (51–91)	0.27	—

Abbreviations: CI=confidence interval; Mcm=minichromosome maintenance; IQR=interquartile range; PSA=prostate-specific antigen.

^*P-value for sensitivity, vs base category (χ² test).

^†P-value for trend across category.